Siponimod may be very similar to [[fingolimod]] but preventing [[lymphopenia]], one of its main side effects, by preventing egress of lymphocytes from lymph nodes. Siponimod may be more selective in the particular sphingosine-1-phosphate receptors (8 in number) that it modulates.<ref>{{cite patent|WO|2008000419|title=S1P Receptor modulators for treating multiple sclerosis |url=http://www.wipo.int/pctdb/en/wo.jsp?WO=2008000419&IA=EP2007005597&DISPLAY=DESC |inventor=Hiestand, Peter C; Schnell, Christian |assignee=Novartis}} {{primary-inline|date=November 2013}}</ref> It is selective for the -1 and -5 SIP receptors.<ref name=Kappos2013/>
